Souhaitez-vous accéder aux communiqués récents ?

Oslo, Norway, 28 April 2026 Vistin Pharma ASA (OSE: VISTN); please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 20 May 2026 at 13:00 CEST. It will not be...

Oslo, Norway, 24 April 2026 Please find attached the Annual Report for 2025 for Vistin Pharma ASA (VISTN). There is no material changes in the financial statement compared to the preliminary full...

Vistin Pharma ASA: First quarter 2026 financial results Oslo, Norway, 24th of April 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2026. First quarter...

Oslo, Norway, 17 April 2026 Vistin Pharma ASA (VISTN) will release its first quarter results on Friday 24th of April 2026. Vistin Pharma will host a conference call for all shareholders and...

Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per...

The Board of Directors will propose for the AGM to get a power of attorney to pay-out an ordinary cash dividend of up to NOK 1.50 per share, to be paid partly with NOK 1 in May and up to NOK 0.50 in...

Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2025. Solid last quarter of 2025 signs-off a...

Oslo, Norway, 5 February 2026 Vistin Pharma ASA will release its fourth quarter and preliminary 2025 results on Thursday 12th of February 2025. Vistin Pharma will host a conference call for all...

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. ...

Oslo, Norway, 24 October 2025 Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2025 results on Friday 31st of October 2025. Vistin Pharma will host a conference call for all...